Welcome!
Vitane Pharma GmbH, Pfaffenrieder Str. 7, D - 82515 Wolfratshausen, Germany - info@vitanepharma.com
CEO MESSAGE:
Vitane aims to become a quality oriented company to meet global requirements in the biopharmaceutical segment. We seek to improve peoples' quality of life through our quality medications by using innovation and manufacturing technologies. Our key focus is on R&D for development of highly biosimilar molecules and target based delivery systems. We are committed to manufacture and supply biopharmaceutical drugs globally through our state-of-the-art manufacturing facility and stringent controlled supply chain system.
We passionately believe that 'Quality is built into the product right from the first step through its manufacturing until its final form, that is tested and released
Thank you for the time to visit us.
Our Services
R&D Strength
A strong multidisciplinary team provides services in development of biopharmaceuticals using Quality by Design (QbD) approach. Vitane also provides extensive development and cGMP compliance services in mammalian and microbial platform. Services include cell line development, cell banking preparation, process development and process characterization using a QbD framework.
Sister Company
Vitane Biologics Private Limited is a Vitane group company incorporated in the year 2006 with focus on Biopharmaceuticals. The objective of the Company is to provide end-to-end solutions for development, technology transfer and manufacture of biopharmaceuticals to cater the global needs. The center has dedicated state of the art R&D and cGMP manufacturing facilities to handle both microbial and cell culture based technology platforms.
Business Lines
Bio-pharmaceuticals including Biosimilars:
- Cell based Biotherapeutics
- Therapeutic Monoclonal Antibodies
- Therapeutic Glycoproteins and Growth Factors
- Vaccines
Dr. Jeetendra Ambulge
CEO & Director of Vitane Biologics
Vitane Biologics Private Limited is a Vitane Group Company
State of the art GLP compliance R&D centre to cater the needs of
co-development of biosimilars and novel biologicals. Process development and scale up from bench scale to 500 L for mammalian cell culture and 2000L for microbial products Generic and novel Formulation developments
R&D has dedicated classified areas:
- Clone Development
- Microbial Fermentation
- Mammalian Cell Culture
- Downstream process
- Analytical method development
- Cell based Assays